120 related articles for article (PubMed ID: 9515817)
1. Reduced lysyl oxidase messenger RNA levels in experimental and human prostate cancer.
Ren C; Yang G; Timme TL; Wheeler TM; Thompson TC
Cancer Res; 1998 Mar; 58(6):1285-90. PubMed ID: 9515817
[TBL] [Abstract][Full Text] [Related]
2. Transforming growth factor beta1 stimulates contrasting responses in metastatic versus primary mouse prostate cancer-derived cell lines in vitro.
Sehgal I; Baley PA; Thompson TC
Cancer Res; 1996 Jul; 56(14):3359-65. PubMed ID: 8764134
[TBL] [Abstract][Full Text] [Related]
3. Elevated expression of caveolin is associated with prostate and breast cancer.
Yang G; Truong LD; Timme TL; Ren C; Wheeler TM; Park SH; Nasu Y; Bangma CH; Kattan MW; Scardino PT; Thompson TC
Clin Cancer Res; 1998 Aug; 4(8):1873-80. PubMed ID: 9717814
[TBL] [Abstract][Full Text] [Related]
4. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
Kaplan PJ; Mohan S; Cohen P; Foster BA; Greenberg NM
Cancer Res; 1999 May; 59(9):2203-9. PubMed ID: 10232609
[TBL] [Abstract][Full Text] [Related]
5. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice.
Zhang F; Lee J; Lu S; Pettaway CA; Dong Z
Clin Cancer Res; 2005 Jun; 11(12):4512-20. PubMed ID: 15958637
[TBL] [Abstract][Full Text] [Related]
6. Smad3 is overexpressed in advanced human prostate cancer and necessary for progressive growth of prostate cancer cells in nude mice.
Lu S; Lee J; Revelo M; Wang X; Lu S; Dong Z
Clin Cancer Res; 2007 Oct; 13(19):5692-702. PubMed ID: 17908958
[TBL] [Abstract][Full Text] [Related]
7. The Src-suppressed C kinase substrate, SSeCKS, is a potential metastasis inhibitor in prostate cancer.
Xia W; Unger P; Miller L; Nelson J; Gelman IH
Cancer Res; 2001 Jul; 61(14):5644-51. PubMed ID: 11454719
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts.
Fizazi K; Yang J; Peleg S; Sikes CR; Kreimann EL; Daliani D; Olive M; Raymond KA; Janus TJ; Logothetis CJ; Karsenty G; Navone NM
Clin Cancer Res; 2003 Jul; 9(7):2587-97. PubMed ID: 12855635
[TBL] [Abstract][Full Text] [Related]
9. Alterations in gene expression profiles during prostate cancer progression: functional correlations to tumorigenicity and down-regulation of selenoprotein-P in mouse and human tumors.
Calvo A; Xiao N; Kang J; Best CJ; Leiva I; Emmert-Buck MR; Jorcyk C; Green JE
Cancer Res; 2002 Sep; 62(18):5325-35. PubMed ID: 12235003
[TBL] [Abstract][Full Text] [Related]
10. Promotion of angiogenesis by ps20 in the differential reactive stroma prostate cancer xenograft model.
McAlhany SJ; Ressler SJ; Larsen M; Tuxhorn JA; Yang F; Dang TD; Rowley DR
Cancer Res; 2003 Sep; 63(18):5859-65. PubMed ID: 14522910
[TBL] [Abstract][Full Text] [Related]
11. Role of interleukin 10 and transforming growth factor beta1 in the angiogenesis and metastasis of human prostate primary tumor lines from orthotopic implants in severe combined immunodeficiency mice.
Stearns ME; Garcia FU; Fudge K; Rhim J; Wang M
Clin Cancer Res; 1999 Mar; 5(3):711-20. PubMed ID: 10100726
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of CD9 expression during prostate carcinoma progression is associated with CD9 mRNA modifications.
Wang JC; Bégin LR; Bérubé NG; Chevalier S; Aprikian AG; Gourdeau H; Chevrette M
Clin Cancer Res; 2007 Apr; 13(8):2354-61. PubMed ID: 17406028
[TBL] [Abstract][Full Text] [Related]
13. Increase of GKLF messenger RNA and protein expression during progression of breast cancer.
Foster KW; Frost AR; McKie-Bell P; Lin CY; Engler JA; Grizzle WE; Ruppert JM
Cancer Res; 2000 Nov; 60(22):6488-95. PubMed ID: 11103818
[TBL] [Abstract][Full Text] [Related]
14. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
Tso CL; McBride WH; Sun J; Patel B; Tsui KH; Paik SH; Gitlitz B; Caliliw R; van Ophoven A; Wu L; deKernion J; Belldegrun A
Cancer J; 2000; 6(4):220-33. PubMed ID: 11038142
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneity of molecular targets on clonal cancer lines derived from a novel hormone-refractory prostate cancer tumor system.
Freedland SJ; Pantuck AJ; Paik SH; Zisman A; Graeber TG; Eisenberg D; McBride WH; Nguyen D; Tso CL; Belldegrun AS
Prostate; 2003 Jun; 55(4):299-307. PubMed ID: 12712409
[TBL] [Abstract][Full Text] [Related]
16. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.
Chung LW; Baseman A; Assikis V; Zhau HE
J Urol; 2005 Jan; 173(1):10-20. PubMed ID: 15592017
[TBL] [Abstract][Full Text] [Related]
17. A novel human cancer culture model for the study of prostate cancer.
Yasunaga Y; Nakamura K; Ko D; Srivastava S; Moul JW; Sesterhenn IA; McLeod DG; Rhim JS
Oncogene; 2001 Nov; 20(55):8036-41. PubMed ID: 11753687
[TBL] [Abstract][Full Text] [Related]
18. Expression profile of an androgen regulated prostate specific homeobox gene NKX3.1 in primary prostate cancer.
Xu LL; Srikantan V; Sesterhenn IA; Augustus M; Dean R; Moul JW; Carter KC; Srivastava S
J Urol; 2000 Mar; 163(3):972-9. PubMed ID: 10688034
[TBL] [Abstract][Full Text] [Related]
19. Elevated levels of prostate-specific antigen (PSA) in prostate cancer cells expressing mutant p53 is associated with tumor metastasis.
Downing S; Bumak C; Nixdorf S; Ow K; Russell P; Jackson P
Mol Carcinog; 2003 Nov; 38(3):130-40. PubMed ID: 14587098
[TBL] [Abstract][Full Text] [Related]
20. Differential metastasis-associated gene analysis of prostate carcinoma cells derived from primary tumor and spontaneous lymphatic metastasis in nude mice with orthotopic implantation of PC-3M cells.
Chu JH; Sun ZY; Meng XL; Wu JH; He GL; Liu GM; Jiang XR
Cancer Lett; 2006 Feb; 233(1):79-88. PubMed ID: 15885894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
